CoChat

Coassembled Chitosan-Hyaluronic Acid Nanoparticles as a Theranostic Agent Targeting Alzheimer’s β-Amyloid

Wang, Wenjuan, Liu, Miaomiao, Gao, Weiqun, Sun, Yan, Dong, Xiaoyan · 2021 · ACS Applied Materials & Interfaces

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

β-Amyloid (Aβ) fibrillogenesis is closely associated with the pathogenesis of Alzheimer’s disease (AD), so detection and inhibition of Aβ aggregation are of significance for the theranostics of AD. In this work, the coassembled nanoparticles of chitosan and hyaluronic acid cross-linked with glutaraldehyde (CHG NPs) were found to work as a theranostic agent for imaging/probing and inhibition of Aβ fibrillization both in vitro and in vivo. The biomass-based CHG NPs of high stability exhibited a wide range of excitation/emission wavelengths and showed binding affinity toward Aβ aggregates, especially for soluble Aβ oligomers. CHG NPs displayed weak emission in the monodispersed state, while they remarkably emitted increased red fluorescence upon interacting with Aβ oligomers and fibrils, showing high sensitivity with a detection limit of 0.1 nM. By comparing the different fluorescence responses of CHG NPs and Thioflavin T to Aβ aggregation, the Aβ oligomerization rate during nucleation can be determined. Moreover, the fluorescence recognition behavior of CHG NPs was selective. CHG NPs specifically bind to negatively charged amyloid aggregates but not to positively charged amyloids and negatively charged soluble proteins. Such enhancement in fluorescence emission is attributed to the clustering-triggered emission effect of CHG NPs after interaction with Aβ aggregates via various electronic conjugations and hydrogen bonding, electrostatic, and hydrophobic interactions. Besides fluorescent imaging/probing, CHG NPs over 360 μg/mL could almost completely inhibit the formation of Aβ fibrils, exhibiting the capability of regulating Aβ aggregation. In-vivo assays with Caenorhabditis elegans CL2006 demonstrated the potency of CHG NPs as an effective theranostic nanoagent for imaging Aβ plaques and inhibiting Aβ deposition. The findings proved the potential of CHG NPs for development as a potent agent for the diagnosis and treatment of AD.

Overview

Integrity signals

Registry

Crossref · 10.1021/acsami.1c17267

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

10 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Cited by

See all 55

Metadata

Authors
Wang, W., Liu, M., Gao, W., Sun, Y., & Dong, X.
Affiliations
Tianjin University (CN)
Corresponding author
  • Sun, Yan
  • Dong, Xiaoyan
Venue
ACS Applied Materials & Interfaces
Published
2021-11-17
Volume
13
Issue
47
Pages
55879-55889
ISSN
  • 1944-8244 (ISSN-L)
  • 1944-8252
OpenAlex
W3214648236
Cited by
53
References
57
Citations by year
2026: 6 · 2025: 13 · 2024: 15 · 2023: 10 · 2022: 9
FWCI
5.37
Type
journal article
Language
en
Open access
closed
Locations
  • ACS Applied Materials & Interfaces (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Tianjin Science and Technology Committee (19JCZDJC36800)
  • National Natural Science Foundation of China (21621004, 21978207)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Physical Sciences › Materials Science › Materials Chemistry › Luminescence and Fluorescent Materials
  • Physical Sciences › Chemistry › Spectroscopy › Molecular Sensors and Ion Detection
Keywords
amyloid-beta, Alzheimer's disease, theranostics, amyloid fibril formation, amyloid oligomers, fluorescence imaging, glutaraldehyde crosslinking, amyloid aggregation inhibition, Caenorhabditis elegans, nucleation rate
MeSH terms
Theranostic Nanomedicine, Alzheimer Disease, Animals, Anti-Bacterial Agents, Biocompatible Materials, Fluorescence, Humans, Hyaluronic Acid, Microbial Sensitivity Tests, Particle Size, Surface Properties, Amyloid beta-Peptides, Caenorhabditis elegans, Cell Line, Tumor, Chitosan, Nanoparticles, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.